Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
May 09, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk...
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
March 11, 2024 07:00 ET
|
Ventyx Biosciences, Inc.
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2...
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
March 07, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
March 06, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
March 04, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
February 27, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash...
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
February 22, 2024 07:00 ET
|
Ventyx Biosciences, Inc.
Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx...
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 21, 2023 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...